Role for Merlin/NF2 in elongation through interaction with the PAF complex
SUMMARY
The PAF complex (PAFC) coordinates transcription elongation and mRNA processing events and its CDC73/parafibromin subunit functions as a tumour suppressor. The NF2/Merlin tumour suppressor functions at the cell cortex and nucleus and is a key mediator of contact inhibition. Here we provide a direct link between nuclear Merlin and transcription elongation controlled by cell-cell adhesion. Merlin interacts with the PAFC in a cell density-dependent manner and tumourderived inactivating mutations in both Merlin and CDC73 mutually disrupt their interaction. Growth suppression by Merlin requires CDC73 and Merlin regulates PAFC association with chromatin in a subset of genes. We also identify by CDC73 affinity-proteomics a role for FAT cadherins in regulating the Merlin-PAFC interaction. Our results suggest that in addition to its function within the Hippo pathway, nuclear Merlin is part of a tumour suppressor network which coordinates postinitiation steps of the transcription cycle of genes mediating in contact inhibition.
INTRODUCTION
Here we show that Merlin interacts with multiple proteins involved in transcription elongation and mRNA processing including the PAFC, the CHD1 chromatin remodeller and the TAT-SF1 elongation/splicing factor suggesting a role of Merlin in coordinating transcription elongation and mRNA processing. We use genomics to identify Merlin-regulated genes and proteomics to show Merlin can regulate the PAFC interactome and identify an interaction between CDC73 and FAT cadherins that is required for Merlin interaction with the PAFC. Our results suggest that Merlin is part of a tumour suppressor network which helps regulate expression of genes mediating contact inhibition by coordinating initiation and post-initiation steps of their transcription cycle in response to cell adhesion.
Because of Merlin's role in contact inhibition, the effects of cell density on Merlin's interactions were studied. HEK293T, IOMM-Lee meningioma (Lee, 1990) and HMLE nontransformed mammary epithelial cells (Elenbaas et al., 2001) stably expressing Flag-Merlin were analysed for their ability to co-IP endogenous proteins in either confluent or very sparse cells, where a minimal number of cell-cell contacts are formed (Figure S1E-D). Cell density had no effect on the interactions with VPRBP, CHD1, TAT-SF1 and the SF3A/B complex ( Figure 1G and S1E-F). In clear contrast, the interaction with the PAFC and RTF1 was strongly reduced under confluent conditions (Figure1G and S1E-F). Conversely, Merlin displays a reduced interaction with AMOT and AMOTL1 under sparse conditions (Figure1G and S1E-F) in agreement with a previous report (Yi et al., 2011) . Thus, cell density can differentially modulate Merlin association with different binding partners, with Merlin's interaction with the PAFC and AMOT family proteins being inversely regulated.
We note that the ability of the PAFC to interact with Merlin in sparse conditions correlates with a slower electrophoretic migration in SDS-PAGE of LEO1 and PAF1 subunits as well as CHD1 ( Figure 1F and S1E-F) that is consistent with phosphorylation. This suggests that signalling originating from cell-cell contacts controls post-translational modification of several Merlin interacting proteins in the nucleus, and at least in the case of the PAFC, this correlates with its ability to interact with Merlin.
The PAFC is required for growth inhibition by Merlin
To map the region of Merlin mediating these novel interactors we expressed GST-fusion proteins of the N-and C-terminal halves of Merlin containing the FERM domain or α-helical and Cterminal domains respectively (Figure 2A ). Merlin associates with the PAFC and CHD1 through its FERM domain whereas the interaction with TAT-SF1 could only be detected with the full length protein suggesting several regions of Merlin are involved in this interaction ( Figure 2B ). As reported, VPRBP also binds to Merlin's FERM domain (Li et al., 2010) whereas AMOT proteins interact with the C-terminal half (Yi et al., 2011) ( Figure 2B ).
The FERM domain is composed of three structurally distinct modules (F1, F2 and F3) that together form a clover-shaped structure. In 'fishing' experiments with recombinant proteins, both wild type Merlin and the FERM domain pulled down the PAFC, CHD1 and VPRBP from cell lysates ( Figure 2C ). The tumour-derived L46R substitution that maps to the F1 lobe disrupted the interaction with the PAFC and CHD1 but only had a partial effect on VPRBP. Similarly, a Merlin deletion mutant lacking the F1 and F2 subdomains of the FERM domain (ΔB41) was unable to interact with the PAFC and CHD1 but could still bind to VPRBP ( Figure 2C ). To further dissect the interactions, a panel of tumour-derived Merlin mutations distributed throughout the protein were tested for their ability to co-IP endogenous proteins. Mutations within F1 and F2 lobes of the FERM domain (L46R, L64P, ΔF118, A211D) or deletion of exons 2 and 3 within the F1 subdomain disrupt Merlin's interaction with the PAFC but not VPRBP or AMOT ( Figure 2D ). The L234R substitution, which lies adjacent to the F2 in the F3 subdomain, does disrupt the interaction with VPRBP (as well as PAFC) ( Figure 2D ). L535P and Q583P in the C-term domain specifically disrupt interaction with AMOT consistent with its interaction with the C-terminus of Merlin (Yi et al., 2011) .
Our findings on the ability of some FERM domain point mutants such as L46R to interact with VPRBP are in contrast to those of Li et al (Li et al., 2010) . We reasoned that different experimental conditions could account for these discrepancies since more stringent lysis and washing conditions (RIPA buffer containing 0.1% SDS) were used in their assays. When similar experiments were performed using RIPA buffer, Merlin's interaction with PAFC, TAT-SF1 and CHD1 can no longer be detected (data not shown). In contrast the Merlin-VPRBP interaction, can still be detected and disruption by FERM domain mutations can now be observed ( Fig. 2E ) in agreement with Li et al (Li et al., 2010) .
Taken together our data suggest that Merlin uses distinct regions of the FERM domain to interact with different proteins, with the F1 and F2 subdomains (B41 domain) mediating the interaction with the PAFC and CHD1 and the F3/FERM-C subdomain primarily mediating the interaction with VPRBP, although substitutions within the other FERM lobes may weaken the affinity for VPRBP and make it more prone to dissociation under certain experimental conditions. We next assessed the ability of our panel of tumour-derived Merlin mutants to inhibit proliferation when expressed in Merlin-deficient cells SF1335 meningioma cells, where both Merlin isoforms 1 and 2 potently inhibit proliferation in clonogenic assays ( Figure 2F) . Surprisingly, many of the tumour-identified mutants were still able to inhibit proliferation as efficiently as wild type Merlin ( Figure 2F ) suggesting these mutations may impair function via decreased protein stability rather than functional activity (Yang et al., 2011) a property that could be overcome by overexpression in our experimental system. Strikingly, only the mutations within the FERM domain (L46R, ΔF118, A211D, L234R) that disrupt the Merlin-PAFC interaction ( Figure 2D ), were unable to inhibit proliferation of SF1335 cells ( Figure 2F ). Splice site mutations are frequently found in NF2 and can lead to deletion of exons 2 and/or 3 (Sainz et al., 1994) . A Merlin deletion mutant lacking amino acids coding for exons 2 and 3 was also defective in its ability to inhibit tumour cell proliferation ( Figure 2F ). Therefore, there is an excellent correlation between the ability of Merlin to inhibit proliferation and its interaction with the PAFC suggesting the Merlin-PAFC interaction is being targeted by inactivating mutations in NF2 tumours.
To study the contribution of the PAFC to growth inhibition by Merlin, Merlin-deficient SF1335 meningioma cells were infected with retroviruses expressing YFP-Ezrin or -Merlin and the cell cycle profile of YFP positive cells was analysed using flow cytometry. Merlin expression led to a pronounced G1 arrest two days after infection whereas expression of Ezrin had no effect ( Figure  3A ). Knock-down of CDC73 with two different siRNA oligos significantly inhibited Merlin-induced G1 arrest ( Figure 3B -D). This strongly suggests that CDC73 is required for Merlin's tumour suppressor function.
We next considered whether tumour derived inactivating mutations in CDC73 might exhibit deficiencies in its interaction with Merlin in co-transfection experiments. In contrast with the CDC73 227x truncation mutants that is unable to interact with Merlin or PAFC subunits, CDC73 413x is unable to bind to Merlin ( Figure 3F ) but still interacts with other PAFC subunits as previously reported (Rozenblatt-Rosen et al., 2005) . Similarly, the CDC73 L95P missense substitution (Bradley et al., 2006; Panicker et al., 2010) had no effect on its interaction with the other PAFC subunits but disrupted the interaction with Merlin ( Figure 3F ). Thus, inactivating mutations in CDC73 disrupt the interaction with Merlin without necessarily influencing the interaction with other PAFC subunits, suggesting that the ability to interact with Merlin is important for CDC73 tumour suppressor function.
CDC73 is a potential substrate of CRL4 VPRBP Merlin interaction with VPRBP E3 ligase complex (CRL4 VPRBP ) in the nucleus is an important mediator of Merlin effects on gene expression (Li et al., 2010) . Because VPBRB and PAFC primarily interact with different FERM subdomains, they would be expected to be in close proximity within a complex with Merlin. We thus tested whether subunits of the PAFC could be targets of ubiquitination by CRL4 VPRBP , as has been described for LATS kinases, themselves Merlin interactors (Li et al., 2014; Yin et al., 2013) .
To examine whether CDC73 is ubiquitylated in vivo, HEK293T cells were transfected with HA-ubiquitin and Flag-baits with or without VPRBP. HA blots of Flag IPs showed the laddering pattern consistent with polyubiquitination on Flag-CDC73 but not on other Merlin interactors tested in parallel, such as AMOT and PAF1. Expression of VPRBP leads to a further increase in polyubiquitination associated with CDC73 but not of PAF1 or AMOT ( Figure 4A ). To test if CDC73 is a direct target of ubiquitylation, similar experiments were performed under denaturing conditions using TAP6-CDC73. Cells were lysed in a guanidinium chloride-containing buffer and subjected to His-tag pulldown with talon beads ( Figure 4B ). Ub-associated laddering was readily observed on CDC73 purified under denaturing conditions that was further increased by VPRBP, consistent with CDC73 being a direct target of the CRL4 VPRBP complex. This effect appears specific to the VPRBP/DCAF1 as expression of other DCAFs had little effect on CDC73 ubiquitination under similar conditions ( Figure 4C ). To test whether Merlin regulates VPRBP's ability to ubiquitilate CDC73, similar experiments were performed over-expressing either Merlin or Ezrin as a control. Merlin expression inhibited, albeit modestly, VPRBP stimulated ubiquitination of CDC73 ( Figure  4D ) consistent with Merlin's inhibition of CRL4 VPRBP activity (Li et al., 2010) .
VPRBP stimulated ubiquitination of CDC73 correlates with their ability to form a complex in vivo as endogenous CDC73 and VPRBP co-IP in multiple cell lines ( Figure 4E ).Taken together, these observations suggest that CDC73 is a target of CRL4 VPRBP mediated ubiquitination and thus Merlin regulation and/or co-recruitment of CRL4 VPRBP may provide a molecular mechanism of PAFC regulation by Merlin.
A gene expression program associated with hypersensitivity to growth inhibition by Merlin
In order to study gene regulation by Merlin, we first characterized expression of Merlin and its interactors in cell lines derived from multiple tumour types. All Merlin interactors tested were found to be ubiquitously expressed ( Figure 5A ). On the other hand, in addition to mesotheliomas and meningiomas, Merlin expression was absent or aberrant in cell lines derived from diverse tumour types ( Figure 5A and S2A-B). Whereas Merlin expression was not detectable in some cell lines, a significant proportion of them (5 out of 11) displayed a faint band of a shorter product in whole cell lysates ( Figure 5A ) or by IP using two different Merlin antibodies ( Figure S2B ). This is consistent with splicing mutations as a mechanism of Merlin inactivation (Ahronowitz et al., 2007) .
When Merlin was expressed ectopically, cell lines with wild type Merlin were insensitive to Merlin expression (with only one exception (1 of 11)) and grew at the same rate as Ezrinexpressing or empty vector controls ( Figure 5B ). In contrast, proliferation of all Merlin-deficient cells (11 of 11 lines) was strongly inhibited by Merlin re-expression ( Figure 5B ). This is consistent with the concept of 'oncogene addiction/tumour suppressor gene hypersensitivity' (Weinstein, 2002) and suggests that in tumours with NF2 mutations, absence of Merlin expression is required for proliferation, regardless of tumour type and/or of additional somatic mutations ( Figure S2A ).
To study how Merlin selectively induced growth arrest in Merlin-deficient cells and shed light on Merlin-regulated genes, we analysed by microarray global gene expression after expressing either Merlin wt or an inactive L46R mutant that is unable to interact with the PAFC ( Figure 2D ) in a set of four cell line pairs derived from different tumour types ( Figure S2C ). Whereas in Merlindeficient cells, re-expression of wt Merlin causes large changes in gene expression, the response in Merlin wt cells is marginal ( Figure 5C ), with only 5 significant changes (fold change >1.5, q<0.05) ( Figure S2D and Table S1 ). In contrast, there was a consistent cross tissue signature of 247 gene changes (85 down, 162 up, fold change >1.5,q<0.05) shared across the 4 different Merlin-deficient cell lines ( Figure 5D and Table S2 ) hereby referred to as the Merlin reexpression/hypersensitivity signature. Therefore, the ability of Merlin to suppress proliferation correlates with its ability to regulate a characteristic gene expression program. Validation of selected Merlin-regulated genes by quantitative RT-PCR is shown in Figure S3 .
Ingenuity pathway analysis revealed the Merlin gene expression signature is highly enriched for genes encoding plasma membrane and extracellular proteins ( Figure 5E ) suggesting a role for Merlin in cellular communication with the microenvironment. Knowledge based pathway analysis by gene set enrichment analysis (GSEA) (Subramanian et al., 2005) revealed Merlin re-expression caused downregulation of genes involved in cell cycle progression and DNA replication ( Figure 5E and S4) consistent with the growth inhibition observed in Merlin-deficient cells. On the other hand, upregulated pathways suggest a transcriptional role for Merlin in inflammation and innate immunity ( Figure 5E and S4). Consistent with a functional link between Merlin and Hippo signaling a conserved YAP transcriptional signature is strongly downregulated by Merlin expression ( Figure  S4C ). Coordinated up/down regulation of several transcriptional signatures also suggests possible functional relationships between Merlin and other transcriptional pathways ( Figure S4C ).
Merlin is involved in the transcriptional response to high cell density
To further define genes regulated by Merlin and their relationship to contact inhibition, microarray experiments were performed after Merlin depletion in HMLE cells at both high and low cell densities. HMLE cells where Merlin expression was inhibited show far fewer significant changes than control cells in response to high cell density ( Figure S5A ): In control cells 801 (449 up, 352 down) genes were significantly regulated (fold change >1.5, p<0.05) compared to only 60 (48 up, 12 down) in Merlin knock-down cells ( Figure S5B and Tables S3 and S4). Validation by qPCR of selected genes regulated by high cell density is shown in Figure S6C .
Comparison of a high cell density gene signature with the Merlin reexpression/hypersensitivity signature shows a significant positive overlap (chi-square, p < 0.001, Figure SED ). Out of the 251 genes regulated by Merlin re-expression in tumour derived cell lines over 20% (52 genes) are regulated by high cell density in the same direction in HMLE cells (Table  S5 ). This is consistent with growth suppression by Merlin being mediated at least partly by some of the same transcriptional changes that mediate contact dependent inhibition of proliferation. Merlin knockdown caused substantially more transcriptional changes in dense cells than in sparse cells consistent with its role in contact inhibition. However, Merlin inhibition in sparse cells still induced substantial changes suggesting Merlin has a wider role in transcription beyond regulation by high cell density ( Figure S5E , Tables S6 and S7 ).
To verify the relevance of these gene signatures, we used the Oncomine concepts platform (https://www.oncomine.org). Genes that are negatively regulated by Merlin in our signatures overlap significantly with overexpressed genes in NF2-deficient cells from a multi cancer cell line study (Garnett et al., 2012) (Figure S5G ) validating the integrity of our signatures. We reasoned that regulated genes moving in the opposite direction in the re-expression/hypersensitivity and knockdown signatures would meet the most stringent criteria for Merlin target genes and are hereby defined as the Merlin core signature ( Figure S5H and Table S12 ). Strikingly, a majority (~ 63%) of the genes within this signature code for cell surface-bound and secreted proteins ( Figure  S5H ) highlighting again a key role for Merlin's transcriptional response in cell communication with the microenvironment.
Merlin regulates PAFC association with the chromatin of a subset of genes
Given Merlin's physical interaction with the PAFC, we next set out to study whether Merlin can regulate the association of PAFC with the chromatin of selected genes upon re-expression in Merlin-deficient cells. In an initial study using EGF-stimulated association with FOS gene by chromatin immunoprecipitation followed by PCR (ChIP-PCR) (Chen et al., 2009) we found that an antibody against the LEO1 subunit of the PAFC gave considerably higher signal-to-noise ratios than the antibodies against CDC73, PAF1 or CTR9 subunits tested (data not shown). Similarly, among the Merlin-deficient cells tested, MDA-MB-231 gave the highest signal to noise ratios. Therefore a LEO1 antibody was used, in parallel with a RNA pol II antibody, for ChIP-followed by massive parallel DNA sequencing (Chip-seq) in MDA-MB-231 cells infected with lentiviruses expressing either Merlin wt or the PAFC interaction-defective L46R Merlin mutant.
The vast majority of RNA Pol II bound genes are also bound by LEO1 ( Figure 6A ), in line with a general role of the PAFC in gene expression (Jaehning, 2010) . When the binding profiles for representative genes are compared, RNA Pol II is found predominantly at the transcription start site (TSS), whereas LEO1 peaks downstream of the TSS and follows RNA Pol II throughout the coding region ( Figure 6B ), consistent with a role of the PAFC in elongation (Jaehning, 2010) .
Expression of wt Merlin regulates the association of LEO1 and RNA Pol II with only a relatively small subset of genes (129 on LEO ChiP, 92 on Pol II ChIP, fold change >+/-1.5) ( Figure 6C , Tables S9 and S10 ). With the cut offs used, 27 genes were identified where Merlin regulates both RNA Pol II and LEO1 binding ( Figure 6D ). The majority of these (20 of 27) were also found regulated by Merlin in the microarray experiment in MDA-MB-231 cells. Plots of the short read coverage for selected Merlin-regulated genes are shown in Figure 6E and validation by ChIP-qPCR in Figure 6G . Taken together these results suggest that Merlin can regulate the ability of the PAFC to associate with selected genes and this correlates with the concomitant regulation of their transcript levels.
Proteomic analysis of the CDC73 interactome highlights a key role for FAT cadherins in Merlin's interaction with the PAFC
In an effort to better understand at the molecular level how Merlin regulates PAFC function we used affinity proteomics to investigate the PAFC interactome and its regulation by Merlin. TAP6-tagged PAF1, LEO1 and CDC73 subunits of the PAFC were stably expressed in Merlin wild-type HT1080 and Merlin-deficient MDA-MB-231 cells. Affinity purification followed by mass spectrometry (AP-MS) identified in all cases the other subunits of the PAFC as the main copurifying proteins. Other proteins were also co-purified, mostly with roles in RNA processing and transcription although surprisingly there also was also a cluster of proteins associated with cell-cell contacts ( Figure S6A and Table S11 ). Many co-purified with all 3 subunits consistent with copurification of the whole PAFC complex, but subunit-specific as well as cell line-specific interactors were also found (e.g. FAT1 and TP53 in Merlin-deficient MDA-MB-231 cells and FTSJ3 and ZZEF1 in Merlin wt HT1080 cells ( Figure S6B -C, Table S11 ).
To further investigate Merlin regulation of the PAFC interactome while avoiding variability associated to inter-cell line comparisons, we performed AP-MS of the TAP6-CDC73 subunit in HEK293T cells co-expressing either Merlin or Ezrin as a control. Most purifying proteins identified were nuclear proteins involved in transcription. However, there also was a significant fraction of proteins associated with cell junctions and cell adhesion ( Figure 7A and Table S12 ) suggesting a direct link between cell-cell contacts and CDC73 function. Using peptide counts as a semiquantitative measurement, Merlin expression decreased association with several proteins, mainly involved in cell adhesion, whereas it increased association of other proteins mainly involved in transcription and chromatin remodeling, including subunits of the Nucleosome Remodeling Deacetylase (NuRD) complex ( Figure 7B and Table S12 ). Therefore, Merlin can both positively and negatively regulate CDC73 association with different sets of proteins.
A comprehensive validation of all these candidate direct or indirect interactions is beyond the scope of this study. However, we were particularly intrigued by the link between CDC73 and cellcell adhesion and in particular with its association with FAT cadherins. FAT1, which like CDC73 functions as a tumour suppressor (Morris et al., 2013) , was found associated with CDC73 by AP-MS in both 293T and MDA-MB-231 cells (Table S11 and S12) and we thus focused on this interaction for this study. Endogenous FAT1 can be readily detected associating with Flag-CDC73 in co-IP experiments and this interaction is not affected by Merlin expression ( Figure 7C ), consistent with the proteomics data in 293T cells. This, together with the observation that FAT1 also copurified with CDC73 in Merlin-deficient MDA-MB-231 cells (Table S11) , suggests CDC73 and FAT1 interact independently of Merlin.
We next investigated whether FAT proteins could regulate the Merlin-PAFC interaction. We used siRNAs to knock-down all FAT isoforms expressed in 293T cells (FAT1, FAT3 and FAT4 as determined by RT-PCR, data not shown) and assessed Flag-Merlin interactions with endogenous proteins in both dense and sparse cells as before (see Figure1 and S1). Strikingly, knock-down of FAT cadherins strongly inhibits Merlin interaction with PAF1, LEO1 and CDC73 PAFC subunits under sparse conditions whereas there was no effect on other Merlin interactors such as VPRBP, AMOT, CHD1 or RTF1. Thus, FAT cadherins are required for Merlin's association with the PAFC.
DISCUSSION
We show that Merlin interacts with a set of nuclear proteins involved in gene expression at post-initiation steps including the PAFC, RTF1, the CHD1 chromatin remodeller and the TAT-SF1 elongation/splicing factor. Interactions between the PAFC, RTF1, CHD1 and TAT-SF1 have been previously reported and suggest a shared role in elongation and splicing (Chen et al., 2009; Sims et al., 2007) .
Several of these Merlin interactors are themselves deregulated in cancer. The CDC73 subunit of the PAFC functions as a tumour suppressor (Newey et al., 2010) and we show CDC73 is required for growth inhibition by Merlin. Furthermore, tumour derived inactivating CDC73 mutations disrupt its interaction with Merlin whereas conversely, inactivating Merlin mutations disrupt the interactions with the PAFC. Furthermore, we show that the interaction between Merlin and the PAFC is regulated by FAT cadherins, which are themselves mutated across various cancer types (Morris et al., 2013; Sadeqzadeh et al., 2014) . Additionally, CHD1 is mutated in prostate cancer (Grasso et al., 2012; Huang et al., 2012; and through TAT-SF1, Merlin interacts with the U2 snRNP complex of the spliceosome, whose components are also frequently mutated in several cancer types (Escobar-Hoyos et al., 2019) .Taken together these findings suggest a function for nuclear Merlin as part of a tumour suppressor network that helps regulate expression of target genes at the level of elongation, chromatin remodelling and RNA processing.
Growth inhibition by Merlin is associated with its ability to regulate a cross-tissue gene expression program that is also regulated by cell density. Merlin interacts with -catenin and Angiomotin junctional proteins and thus is well poised to respond to signals originating from cellcell contacts. Cell density is known to regulate Merlin phosphorylation and activity and we show that subunits of the PAFC as well as CHD1 are also likely phosphorylated in a cell density dependent manner. Moreover, Merlin's ability to interact with the PAFC is regulated by FAT cadherins and correlates with the ability of FATs to associate with the CDC73 subunit of the PAFC. Taken together, these results are consistent with a model whereby multiple signals originating from cell-cell contacts converge at the level of Merlin-PAFC interaction to mediate a growth inhibitory gene expression program associated with contact inhibition of proliferation (Figures S7) .
Although transmembrane proteins with a large extracellular domain, FATs are processed proteolytically by mechanisms similar to Notch and nuclear localization of FAT1 cytoplasmic tail and association with transcription regulators has been reported (Fanto et al., 2003; Feng and Irvine, 2009; Hou and Sibinga, 2009; Magg et al., 2005; Sadeqzadeh et al., 2011) . Interestingly, CDC73/Parafibromin has been reported to interact with the Notch intracellular domain (as well as B-catenin and Gli1) (Kikuchi et al., 2016) . Conversely although CDC73 is predominantly nuclear, it has also been detected in the cytoplasm in some contexts (Agarwal et al., 2008; Jo et al., 2014) . Future studies should shed further light on the nature of the interaction between the CDC73 and FAT tumour suppressor proteins but their association with renal defects may provide an independent genetic link: in addition to cancer, FAT1 mutations are linked to glomerulotubular nephropathy and fat1 knockdown in zebrafish causes pronephric cysts (Ciani et al., 2003; Gee et al., 2016) whereas CDC73 mutations in HPT-JT syndrome are associated with renal lesions in 20% of cases, most commonly cysts (Jackson et al., 1993) .
Elongation control plays a crucial role in regulated gene expression and provides an additional regulatory node in the transcription cycle to exert combinatorial control of transcription levels (Jonkers and Lis, 2015; Nechaev and Adelman, 2011) . In contrast to initiation, where target gene specificity can be provided by sequence specific transcription factors, far less is known about how elongation and RNA processing can be differentially regulated, with likely multiple mechanisms involved for individual genes or network of genes (Jonkers and Lis, 2015; Nechaev and Adelman, 2011) . The PAFC travels with RNA Pol II on most actively transcribed genes but Merlin can target the PAFC to associate with only a subset of genes. We propose that Merlin may function as a co-factor to target a protein complex involved in elongation and RNA processing to a particular subset of genes regulated by cell adhesion.
The molecular mechanisms involved remain to be determined but CRL4 VPRBP -mediated ubiquitination is likely to play a role. Merlin independently interacts with both CRL4 VPRBP and PAFC and is thus expected to bring them into the same macromolecular complex and we show that the CDC73 subunit of the PAFC is a likely target of CRL4 VPRBP -mediated ubiquitination. How this modification is regulated in vivo and how it affects PAFC function remains to be determined. It is worth noting that VPRBP was originally identified as the HIV VPR interacting protein and that many of the Merlin interactors identified in our study, including TAT-SF1, PAFC and CHD1, are used by HIV during its transcription cycle (Gallastegui et al., 2011; Sobhian et al., 2010; Vanti et al., 2009) . Although the role of VPR in the HIV cycle is still unclear, it is tempting to speculate that it may function in a manner equivalent to Merlin to target VPRBP to regulate PAFC-mediated transcription of viral target genes.
The genomics data of this study is consistent with the known role of Merlin as an upstream regulator the Hippo pathway pathway (Cooper and Giancotti, 2014; Ma et al., 2019) as many of the genes in our Merlin signatures are known YAP target genes. Our study suggest that Merlin may provide independent layers of regulatory control in the transcription cycle of some genes ( Figure S7 ): According to our proposed model, Merlin at the membrane primarily regulates LATS phosphorylation of YAP/TAZ to promote TEAD-dependent Pol II recruitment and transcription initiation, whereas nuclear Merlin, through its interaction with the PAFC (as well as CHD1, RTF1, TAT-SF1 and others) may also regulate post-initiation steps such as pause release, elongation rate and/or RNA processing in a subset of target genes ( Figure S7 ).
Understanding these multiple regulatory nodes within the Hippo pathway, how the function of nuclear Merlin is intertwined with its membrane function and how it helps coordinate the different steps of the transcription cycle of selected genes through its interaction with a network of nuclear tumour suppressor proteins will be important to be able to provide new therapeutic opportunities for NF2 tumours as well as the many human cancers where this pathway is deregulated
EXPERIMENTAL PROCEDURES

Interaction assays
Cells were lysed in PBS-E LB (1x PBS, 1% TX100, 1 mM EDTA, 1 mM DTT, Protease Inhibitor cocktail (Roche) and Phosphatase Inhibitor solution (Sigma)). When indicated RIPA buffer (PBS-E LB+ 0.1% SDS, 0.5% DOC,) was used. Flag (M2) agarose beads (Sigma-Aldrich), glutathione sepharose beads (GE Healthcare), or a combination of the appropriate antibody and Protein A or G sepharose beads (GE Healthcare) were used to immunoprecipitate tagged or endogenous proteins from cleared lysates. For cell density experiments, when 10cm dishes reached ~90% confluency, either medium was changed (Dense) or split to 4-5x15cm dishes (Sparse) and cells harvested 12-15 hrs later. Immunoprecipitates were extensively washed with lysis buffer minus inhibitors, drained and resuspended in NuPAGE LDS sample buffer (Life Technologies).
Clonogenic assays
Cells were infected with retroviruses or lentiviruses expressing either Merlin or Ezrin, seeded at different densities in 6-well plates and stained with crystal violet (0.5% in 10% Methanol) 7-14 days later when the Ezrin or empty vector control wells reached confluency.
Flow-cytometry
Cells were fixed in 70% Ethanol two days after retroviral infection with YFP-Ezrin/Merlin and cell cycle profiles assessed by propidium iodide (PI) staining. The cell cycle of YPF-positive cells is shown, no changes were seen in the YFP-negative population of cells. Where indicated cells were transfected with siRNA, infected 24 hrs later with retroviruses expressing YFP constructs and harvested 48 hrs later for FACS analysis. Ubiquitination assays. Cells were co-transfected with pMT123-HA-ubiquitin (Treier et al., 1994) and lysed 2 days later. For denaturing conditions, cells were lysed with Guanidine lysis buffer (6M Guanidine-HCl, 50mM NaHPO4 buffer pH:8, 0.3M NaCl, 0.1% TX-100, 10mM imidazole, 5mM b-Mercaptoethanol), briefly sonicated and incubated after centrifugation with TALON beads. Beads were washed once with Guanidine LB and 3 times with Urea wash buffer (8M urea, 50mM NaHPO4 buffer pH:8, 0.3M NaCl, 0.1% TX-100, 10mM imidazole, 5mM b-Mercaptoethanol). For native conditions, cells were lysed in RIPA buffer (1x PBS, 1% TX100, 0.1% SDS, 0.5% Sodium deoxicholate,1 mM EDTA, 1 mM DTT, with Protease and Phosphatase Inhibitors). Cleared lysates were incubated with Flag beads for 1-2 hours and beads washed 4 times with RIPA LB. Drained beads were resuspended in LDS sample buffer and run in Nupage 4-12% gels. After gel transfer, membranes were probed with anti-HA-peroxidase (Roche-12013819001) and developed by chemiluminescence or with FLAG-Dylight680 and HA-IRDye800 (Rockland) and developed with the Odissey imaging system (Lycor).
Yu, M., Yang, W., Ni, T., Tang, Z., Nakadai, T., Zhu, J., and Roeder, R.G. (2015) . RNA polymerase IIassociated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science 350, 1383-1386. Zhang, N., Bai, H., David, K.K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R.A., and Pan, D. (2010) . The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19, 27-38. At the membrane, Merlin associates with cell-cell contact associated proteins such as a-catenin at adherens junctions and AMOT proteins at tight junctions whereas FAT cadherins may associate with the CDC73 subunit of the PAF complex at distinct adherens junctions. Merlin at the membrane primarily functions to regulate LATS-dependent phosphorylation and inactivation of YAP/TAZ. Upon Merlin inactivation (e.g. upon loss of cell-cell contacts), YAP/TAZ translocates to the nucleus to mediate TEAD dependent recruitment of Pol II and transcription initiation. In the nucleus, Merlin interacts with the CRL4 VPRBP E3 ubiquitin ligase and with proteins involved in transcription elongation and RNA processing including the PAFC, CHD1, RTF1 and TAT-SF1 (this study). Through these interactions, Merlin regulates post-initiation events such as pause release, elongation rate and/or RNA processing in at least a subset of target genes. Merlin could use CRL4 VPRBP mediated ubiquitination of some associated proteins (such as CDC73 and/or other CRL4 VPRBP substrates) to regulate their properties and/or function within this macromolecular complex. AMOT also has dual membrane/cytoplasm and nuclear roles and is required for YAP transcriptional activity of some target genes (Hong, 2013; Ragni et al., 2017) . ZO-2, another tight-junction associated protein also interacts with YAP in the nucleus (Oka et al., 2010) . It is therefore possible that separate membrane/cytoplasm and nuclear functions of several of its components is a common feature of the Hippo pathway that allows for independent layers of regulatory control. Note that reported additional interactions of FAT with Hippo pathway components are not shown (Martin et al., 2018; Ragni et al., 2017) but also suggest multiple layers of regulation of the Hippo pathway by FAT proteins. Merlin mays also cooperate/antagonize with transcription factors other than YAP/TAZ (not shown). AJ: adherens junctions, TJ: tight junctions. Table S1 . Genes regulated by Merlin expression in Merlin wild type cells Table S2 . Genes regulated by Merlin expression in NF2 mutant cells Table S3 . Genes regulated by high cell density in control siRNA HMLE cells Table S4 . Genes regulated by high cell density in siNF2 HMLE cells Table S5 . Genes regulated in the same direction by Merlin re-expression in 4 NF2 mutant cell lines and high cell density in HMLE cells Table S6 . Genes regulated by NF2 knockdown in dense HMLE cells Table S7 . Genes regulated by NF2 knockdown in sparse HMLE cells Table S8 . Merlin core gene signature Table S9 . Genes where Pol II association is regulated by wild type vs L46R Merlin expression in MDA-MB-231 by ChIP-seq Table S10 . Genes where LEO1 association is regulated by wild type vs L46R Merlin expression in MDA-MB-231 by ChIP-seq. Table S11 . Proteins identified by mass spectrometry with TAP6-CDC73, -PAF1 or -LEO1 in HT1080 or MDA-MB-231 cells Table S12 . Proteins identified by mass spectrometry after affinity purification of TAP6-CDC73 in HEK293T cells co-expressing either Ezrin or Merlin
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SUPPLEMENTARY METHODS
Antibodies and constructs
AMOTL1 (HPA001196), Flag (M2), FAT1 (HPA001869) and HA-peroxidase antibodies were obtained from Sigma. Merlin (E-2 and A-19), RNA Pol2 (N-20), SPT16 (H-4), HA (Y-11), MYC (A-14) and anti-goat-HRP (sc-2020) antibodies from Santa Cruz and p21 (05-345) from Millipore. AMOT (303A), CDC73 (170A), CHD1 (218A), CTR9 (395A), DDB1 (462A), LEO1 (175A), Merlin iso1 (A578), Merlin iso2 (A579), PAF1 (172A), PELP1 (180A), RTF1 (179A), YAP (309A), SF3A3 (507A), SF3B1 (997A), SF3B3 (508A), TAT-SF1 (023A), VPRBP (887A and 888A), FAT1 (402A and 403A) antibodies were from Bethyl Laboratories, FLAG-Dylight680 and HA-IRDye800 from rockland. Anti-mouse-HRP (NA 931) and anti-rabbit-HRP (NA934) were obtained from Amersham. cDNAs were cloned into the pENTR vector (Invitrogen) and transferred to Gatewaycompatible expression vectors using recombination-mediated Gateway technology (Invitrogen). Mutations were generated using the QuikChange site-directed mutagenesis kit (Stratagene).
Cell culture and virus generation
Dulbecco's Modified Eagle's Medium (DMEM) and Roswell Park Memorial Institute (RPMI) Medium was supplemented with 10% FBS; DMEM F12 was supplemented with 5% HS, 20 ng/ml EGF, 0.5 µg/ml hydrocortisone, 100 ng/ml cholera toxin and 10 µg/ml insulin. All cells were grown in DMEM except for 786-0, 8505C, ACHN, B-CPAP, CAKI-1, CGTH-W-1, S-117 and SN12C which were grown in RPMI, and HMLE and MCF10A which were grown in DMEM F12. Lentiviruses were generated by transient transfection of HEK293T cells with the lentiviral construct, pMD.G (VSV-G) and p8.91 (gag-pol) packaging vectors. Virus-containing medium was harvested 48 h and 72 h after transfection and supplemented with 5 µg/ml Polybrene (hexadimethrine bromide, Sigma-Aldrich). Cells were transduced with lentivirus and selected 24 hours later with 2.5 mg/ml puromycin (Sigma-Aldrich) or 10 mg/ml Blasticidin (Melford). Retroviruses were generated by transient transfection of the Phoenix ecotropic cell line and virus was collected and cells infected as above. Cell lines expressing the ecotropic receptor EcoR where generated by transduction with amphotropic EcoR retroviruses and selection with Blasticidin. Retroviruses and lentiviruses were titered by infection with serial dilutions in HEK293T and/or IOMM-Lee cells.
Transfections 2x10^6 HEK293T cells were transfected with 2ug plasmid DNA and 1 mg/ml polyethylenimine (PEI, Polysciences) mixed at a 1:5 ratio in OptiMEM (Gibco). After 30 min incubation at RT the transfection solution was added to cells cells seeded 2 h prior. Fresh medium was added 16-24 h after transfection and cells harvested the day after. For RNAi knockdown experiments cells were seeded 2 h prior transfection using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's recommendations using 10 nM siRNA oligos and lysed 3 days later. Stealth RNAi Negative Control Medium GC Duplex (Invitrogen) was used as control oligo. Stealth siRNA oligos were from Invitrogen and are listed below. Smartpools were obtained from Thermo Scientific.
Purification of recombinant proteins and 'Fishing' experiments
Baculoviruses expressing Merlin wild type and variants expressed as GST-fusions proteins were generated using the FastBac method (Invitrogen). 3 days after infection, Sf9 cells were lysed in PBS-E LB and clarified lysates purified with Gluthathione Sepharose beads as above. After extensive washing, beads and bound proteins were stored in 50% glycerol at -20 °C. 10 µl of beads were added to lysates, incubated for 2 h, washed and eluted with LDS sample buffer. Copurifying proteins were detected by Western blotting with the appropriate antibodies.
Nuclear fractionation/ enrichment
HT-1080 fibrosarcoma cells were infected with lentiviruses expressing shRNA hairpins targeting non-silencing control, NF2, VPRBP or PELP1 and selected in 2.5 µg/ml puromycin. shRNAmir sequences were from pGIPZ library (Open Biosystems): Non-silencing: CTCTCGCTTGGGCGAGAGTAAG NF2-1: CCGGTGTGAACTACTTTGCAAT NF2-3: CGCAGCAAGCACAATACCATTA VPRBP : CGCACTTCAGATTATCATCAAT PELP1: AAGGATTTGACAGTTATTAATA. Cells were washed twice with cold PBS, washed once quickly with hypotonic buffer without Triton X-100 and lysed in hypotonic buffer (20 mM Hepes (pH 7.5), 10 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 0.1% (v/v) Triton X-100, 20% Glycerol (v/v)) on ice for 10 min. Cells were scraped and spun at 150 g for 10 min at 4°C. The supernatant was kept as the cytosolic fraction. The nuclear pellet was washed once in hypotonic buffer without Triton X-100 but supplemented with 1 mM DTT, phosphatase inhibitor (Halt, Thermo Scientific) and protease inhibitor (Roche) and lysed in 5x pellet volume of hypertonic buffer (20 mM Hepes (pH 7.5), 0.5 M NaCl, 1.5 mM MgCl2, 1 mM EDTA, 20% Glycerol (v/v)) for 30 min at 4°C. The lysate was subsequently spun at 16000 g for 10 min. The supernatant yielded the nuclear fraction. The pellet was lysed in 20 μl 2x LDS for nuclear insoluble fraction.
Gene expression analysis
Gene expression profiles were determined using Whole-transcript Expression Analysis on GeneChip® Human Gene 2.0 ST Arrays (Affymetrix). Total RNA was extracted 48hours after lentiviral infection using the RNeasy Mini Kit (Qiagen). cDNA was generated using the WT Expression Kit (Ambion) and labeled using the GeneChip WT Terminal Labeling Kit (Affymetrix). The hybridisation protocols were performed on GeneChip Fluidics Station 450, and scanned using the Affymetrix GeneChip Scanner. Expression data was pre-processed and normalised using 'affy' and the RMA algorithm (Gautier et al., 2004) and differential expression determined using 'limma' (Smyth, 2005) . Unless otherwise stated, significant difference of expression is taken as q < 0.05 (false discovery rate adjusted) and fold-change greater than +/-1. (Li and Durbin, 2010) . Read counts were then generated for each gene in a sample by selecting the longest known transcript and an additional 400bp upstream of the TSS. Further processing was then undertaken using the R statistical programming language (version 2.14.2) (R Development Core Team, 2012) including the DESeq bioconductor package (version 2.11) (Anders and Huber, 2010) . After normalising by library size the antibody control count from each gene was deducted from each sample. Differential enrichment statistics were then calculated using the DESeq package allowing for pooling of samples to compensate for lack of replicates. RNA Pol2 and LEO1 samples were compared independently. All plots were created using the NGSplot graphing toolkit (Liu X., 2012) . Data were visualized at representative loci using UCSC genome browser. Data has been deposited in EMBL-EBI as SRP035339.
Statistical analysis
Data are represented as mean values and the error bars indicate ±SD. Groups were compared by two-tailed unpaired t-test. The significance is indicated as *** for P<0.001, ** for P<0.01 and * for P<0.05. . For expression data multiple testing correction (q-values) were calculated using the Benjamini-Hochberg false dicovery rate (FDR).
Affinity purification and Mass spectrometry
Tandem affinity purification (TAP) for Merlin was performed from 10 x 15 cm dishes of HEK293T cells, transiently transfected with pcDNA3-TAP6 constructs. For CDC73, 20 x 15 cm dishes of HEK293T stably expressing TAP6-CDC73 (pLEX-MCS, Open Biosystems) and either Merlin or Ezrin (pLentiCMVBlast, addgene 17486) were used. The TAP6-tag contains 3x streptactin, 2x histidine, SBP and FLAG tags. Cells were lysed in PBS-E lysis buffer (LB) Clarified pooled lysates were incubated with Streptavidine Sepharose beads (GE Healthcare) and washed extensively with PBS containing 0.1% TX-100. Bound proteins were first eluted with 2 mM Biotin and then LDS sample buffer. Biotin eluates were TCA precipitated, separated on 4-12% NuPAGE gels (Life Technologies) and stained with SimplyBlue SafeStain (Life Technologies). Gels were cut along the lanes in several pieces, and proteins were digested in-gel with trypsin as described previously (Rosenfeld et al., 1992) (donatello.ucsf.edu/ingel.html) . The extracted digests were vacuum-evaporated and resuspended in 10 µl of 0.1% formic acid in water, except the slice containing the bait, that was resuspended in 30 µl. The digests were separated by nano-flow liquid chromatography using a 75 µm x 150 mm reverse phase C18 PepMap column (Dionex-LC-Packings, San Francisco, CA) at a flow rate of 300 nl / min in a NanoLC-1D Proteomics high-performance liquid chromatography system (Eksigent Technologies, Livermore, CA, USA) equipped with a FAMOS autosampler (Dionex-LC-Packings, San Francisco, CA).
Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile. Following equilibration of the column in 5% solvent B, 5 µl of the digests were
CDC73 interactome
The final interactome list contained proteins that were identified with at least 2 unique peptides with the CDC73 bait but not an unrelated bait purified in parallel. Label-free quantification was estimated by spectral counts that were normalised to the CDC73 bait. A normalisation factor of 15% was calculated (Merlin-CDC73/Ezrin-CDC73=1.15) and used to adjust the spectral counts of the Ez pulldown. A Merlin/Ezrin fold change was calculated for the proteins detected in both pulldowns. Proteins detected in one pulldown only with at least 3 peptide counts were defined as upregulated (absent in Ez) or downregulated (absent in NF2) to a higher degree than if detected in both pulldowns. The protein list was loaded into DAVID for functional annotation analysis with Gene Ontology (GO) terms. Top ranked enriched functional clusters of GO terms were selected and used to fully annotate the protein interactome list within the QuickGO browser for Gene Ontology terms and annotations. The protein list was then loaded into the STRING database of functional protein association networks where textmining, experiments, and databases were used as active interaction sources to generate a network at medium confidence. The network was exported and loaded into Cytoscape 3.3.0 for integrating the network with attribute data (fold change regulation and functional terms) and visualizing these. 
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